- Home
- Publications
- Publication Search
- Publication Details
Title
Burosumab: Current status and future prospects
Authors
Keywords
-
Journal
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
Volume -, Issue -, Pages 101826
Publisher
Elsevier BV
Online
2023-10-01
DOI
10.1016/j.beem.2023.101826
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level
- (2023) Erik A Imel et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia
- (2022) Leanne M Ward et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1)
- (2022) Xiuying Bai et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Health-related quality of life of X-linked hypophosphatemia in Spain
- (2022) M. I. Luis Yanes et al. Orphanet Journal of Rare Diseases
- Long-term use of burosumab for the treatment of tumor-induced osteomalacia
- (2022) C. Crotti et al. OSTEOPOROSIS INTERNATIONAL
- Approach to Hypophosphatemic Rickets
- (2022) Sarah A Ackah et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia
- (2021) Raja Padidela et al. CALCIFIED TISSUE INTERNATIONAL
- Burosumab treatment for fibrous dysplasia
- (2021) Anne Gladding et al. BONE
- Burosumab for Tumor‐Induced Osteomalacia: Not Enough of a Good Thing
- (2021) Iris R Hartley et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Burosumab for Pediatric X-Linked Hypophosphatemia
- (2021) Erik A. Imel Current Osteoporosis Reports
- Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
- (2021) Karine Briot et al. RMD Open
- Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia
- (2021) Agnès Linglart et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- New Therapies for Hypophosphatemia-Related to FGF23 Excess
- (2020) Diana Athonvarangkul et al. CALCIFIED TISSUE INTERNATIONAL
- Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia
- (2020) Yasuo Imanishi et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Burosumab for the Treatment of Tumor‐Induced Osteomalacia
- (2020) Suzanne M Jan de Beur et al. JOURNAL OF BONE AND MINERAL RESEARCH
- FGF23 signalling and physiology
- (2020) Bryan B Ho et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial
- (2019) Michael P Whyte et al. Lancet Diabetes & Endocrinology
- Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial
- (2019) Erik A Imel et al. LANCET
- Burosumab treatment of children with X-linked hypophosphataemic rickets
- (2019) Rebecca J Gordon et al. LANCET
- Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
- (2019) Dieter Haffner et al. Nature Reviews Nephrology
- Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period
- (2019) Anthony A. Portale et al. CALCIFIED TISSUE INTERNATIONAL
- Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial
- (2019) Karl L Insogna et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Burosumab: First Global Approval
- (2018) Yvette N. Lamb DRUGS
- Validation of a Novel Scoring System for Changes in Skeletal Manifestations of Hypophosphatasia in Newborns, Infants, and Children: The Radiographic Global Impression of Change Scale
- (2018) Michael P Whyte et al. JOURNAL OF BONE AND MINERAL RESEARCH
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis
- (2018) Karl L Insogna et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Burosumab: At Long Last, an Effective Treatment for FGF23-Associated Hypophosphatemia
- (2018) Michael Collins JOURNAL OF BONE AND MINERAL RESEARCH
- Burosumab Therapy in Children with X-Linked Hypophosphatemia
- (2018) Thomas O. Carpenter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23
- (2015) Erik A. Imel et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia
- (2014) Thomas O. Carpenter et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice
- (2010) Yukiko Aono et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Therapeutic Effects of Anti-FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia*
- (2009) Yukiko Aono et al. JOURNAL OF BONE AND MINERAL RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started